AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health
VANCOUVER, British Columbia, and BOSTON, November 19, 2020 – AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that
Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team
New Investors Include Casdin Capital and Tekla Capital Antibody Development Experts Bill Brondyk, PhD, Named Chief Scientific Officer and Colin Giles, PhD, Chief Development
Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health
Platform Leverages Best-in-Class Technologies from AbCellera, Twist Bioscience and WuXi Biologics BOSTON, Mass. – July 16, 2020 – Invetx, a pioneer in protein-based therapeutics for
Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats
SOUTH SAN FRANCISCO and BOSTON, Mass. – July 16, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering
Invetx Announces $15 Million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development
Anterra Capital leads financing to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma Global biologics CDMO WuXi Biologics makes equity investment
